Looking for research-grade compounds?
Ipamorelin peptide research is the study of a synthetic pentapeptide that earned a specific distinction in the growth hormone literature: selectivity. Earlier growth hormone-releasing peptides could raise growth hormone (GH), but they also raised cortisol, prolactin, or other pituitary hormones, muddying any experiment trying to isolate a GH effect. Ipamorelin peptide research, beginning with its characterization at Novo Nordisk in 1998, showed comparable GH-releasing potency with a far cleaner hormonal profile in animal models. This guide reviews what that selectivity means, what the human data do and do not show, and where the compound stands with regulators today.
Ipamorelin is a synthetic pentapeptide — five amino acid units — with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its molecular formula is C38H49N9O5 and its molecular weight is about 711.9 g/mol. It was developed at Novo Nordisk and is also identified in the older literature by the development code NNC 26-0161.
Two structural choices define it. It was derived from the GHRP family but lacks the central Ala-Trp dipeptide of GHRP-1, and its N-terminus carries Aib — aminoisobutyric acid, a non-standard amino acid — which restored potency lost when the sequence was shortened. Three of its five residues are non-natural or modified, which is why identity testing matters so much for this compound.
Ipamorelin is classified as a growth hormone secretagogue (GHS) and, more precisely, as a ghrelin mimetic: it acts at the same receptor as ghrelin, the endogenous peptide best known for its role in appetite and GH release. It is not a GHRH analog, not a form of growth hormone itself, and not a SARM — distinctions that matter when comparing it with compounds such as CJC-1295, which act on an entirely different receptor.
Ipamorelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary and in hypothalamic circuits. In cellular models, GHS-R1a activation signals mainly through Gq, raising intracellular calcium and activating protein kinase C pathways, which triggers the release of stored GH from somatotrophs.
That route contrasts with the GHRH pathway, which signals mainly through cyclic AMP. The two pathways converge on the same cell and output — a pulse of GH — through different receptors. That complementarity is the mechanistic basis for research interest in combining a GHRH analog with a secretagogue; it is not clinical evidence, and no published human randomized trial has tested ipamorelin combined with a GHRH analog.
GH is normally secreted in pulses governed by hypothalamic timing. The preclinical work indicates ipamorelin amplifies GH output within that existing architecture — a single, discrete episode of release, then a return toward baseline. The detailed pulse measurements come from rat and swine models, not human studies, and claims that it changes pulse frequency in humans are not supported by the published record.
The foundational paper in ipamorelin peptide research is Raun and colleagues, published in the European Journal of Endocrinology in 1998 (volume 139, pages 552–561), reporting work from Novo Nordisk. Its findings, in summary form:
That last finding is why the paper described ipamorelin as the first selective growth hormone secretagogue. For a researcher, selectivity is an experimental-design advantage: if a secretagogue also moves cortisol, every downstream result carries a glucocorticoid confounder. What selectivity does not do is establish any clinical benefit — it describes which hormones moved in animal models, nothing more.
| Feature | Ipamorelin | GHRP-6 | GHRP-2 |
|---|---|---|---|
| Class | Ghrelin mimetic, GHS-R1a agonist | Ghrelin mimetic, GHS-R1a agonist | Ghrelin mimetic, GHS-R1a agonist |
| GH potency in early models | Comparable to GHRP-6 | Reference compound in Raun 1998 | More potent, lower efficacy in swine model |
| ACTH / cortisol in animal studies | No significant change, even at high multiples of GH-effective exposure | Elevated | Elevated |
| Other pituitary hormones | No significant change in FSH, LH, prolactin, or TSH in the characterization work | Broader pituitary effects reported | Prolactin effects reported |
| Human evidence | Small pharmacokinetic study; one Phase 2 proof-of-concept trial in a GI indication | Limited human pharmacology work | Limited human pharmacology work |
| FDA status | Not FDA-approved for any indication | Not FDA-approved for any indication | Not FDA-approved for any indication |
The human record is thin, old, and mostly pharmacological — most online summaries borrow credibility from the animal selectivity data and spend it on human claims the trials never tested.
The core human study is Gobburu and colleagues (1999), a dose-escalation study in healthy male volunteers using short infusions across five dose levels, eight subjects per level. Exposure was dose-proportional. The terminal half-life was short — about 2 hours — with clearance of about 0.078 L/h/kg and a steady-state volume of distribution of about 0.22 L/kg. The GH response was a single episode peaking at about 0.67 hours, then declining. In humans, this is a short-acting, pulse-like compound — far from the multi-day profile of long-acting GHRH analogs — and any source describing it as long-acting contradicts its primary literature.
The biggest human trial of ipamorelin was not about body composition, recovery, or aging. It was a Phase 2, multicenter, double-blind, placebo-controlled proof-of-concept study in postoperative ileus — delayed bowel function after surgery — led by Beck and colleagues and published in the International Journal of Colorectal Disease in 2014 (ClinicalTrials.gov NCT00672074). The rationale was ghrelin-receptor biology: GHS-R1a signaling has promotility effects in the gastrointestinal tract, a line of work also supported by rodent ileus studies such as Greenwood-Van Meerveld and colleagues (2012).
The trial enrolled 117 patients undergoing bowel resection, with 114 in the safety and modified intent-to-treat populations. Its endpoint was time to tolerance of a standardized solid meal: a median of 25.3 hours on ipamorelin versus 32.6 hours on placebo — not statistically significant (p = 0.15). It did not establish efficacy, and development for that indication did not lead to an approved product. This trial belongs in any honest profile: it is the largest controlled human dataset the compound has, and its result is negative.
Johansen and colleagues (1999, Growth Hormone & IGF Research) reported longitudinal bone growth in rats treated with ipamorelin — consistent with GH-axis stimulation in a growing animal, and not evidence about bone outcomes in adult humans. Across the whole record, the pattern is consistent: strong animal pharmacology, minimal controlled human evidence, and no outcome trials for the uses most commonly marketed online.
FDA approval: Ipamorelin is not approved by the U.S. Food and Drug Administration for any indication. No approved drug product contains it. It is an investigational compound, full stop.
Compounding history: In September 2023, FDA placed ipamorelin acetate in Category 2 of its interim Section 503A bulks list — for substances the agency said raised significant safety concerns — making it ineligible for 503A compounding. In 2024, FDA’s Pharmacy Compounding Advisory Committee voted against recommending it for that list. Its nomination was later withdrawn and its interim listing has since changed; FDA also lists it separately under its 503B interim policy. None of those moves is an approval or a finding of safety — check FDA’s current listings directly, as this status has moved several times. In August 2026, FDA also issued warning letters to several online peptide sellers over marketing of unapproved products including ipamorelin.
Anti-doping: Ipamorelin is named on the World Anti-Doping Agency Prohibited List under S2, peptide hormones, growth factors, related substances and mimetics, as a growth hormone secretagogue. It is prohibited at all times, in and out of competition, and classified as a non-specified substance. This is not theoretical: in 2026 the International Testing Agency reported an adverse analytical finding for ipamorelin from an out-of-competition sample collected during the Commonwealth Games period, resulting in a mandatory provisional suspension. Tested athletes have no research-use exception.
Research-use-only framing: None of the above changes with a label. As our overview of what research use only actually means explains, RUO describes a material’s intended laboratory purpose — it does not create an approved human use, and marketing a compound with human-use claims is exactly what drew the 2026 warning letters.
Researchers comparing GH-axis tools can browse the research peptide catalog, and the CJC-1295 No DAC + Ipamorelin research product page carries batch documentation for the blend format in which ipamorelin is commonly supplied for laboratory work.
No. Ipamorelin is not FDA-approved for any indication, and no approved drug product contains it. Its largest human trial, in postoperative ileus, did not meet statistical significance, and development for that indication did not lead to an approved product.
In the original animal characterization (Raun et al., 1998), ipamorelin released GH with potency comparable to GHRP-6 but, unlike earlier secretagogues, produced no significant change in ACTH, cortisol, FSH, LH, prolactin, or TSH — even at exposures far above those needed for GH release. That is a preclinical pharmacology finding about which hormones moved, not evidence of any clinical benefit.
About 2 hours, from the human pharmacokinetic study by Gobburu and colleagues (1999) in healthy male volunteers. The GH response in that study was a single episode peaking at about 0.67 hours. Ipamorelin is a short-acting compound.
Different receptors, same pituitary cell type. Ipamorelin acts at GHS-R1a, signaling mainly through calcium and protein kinase C; CJC-1295 acts at the GHRH receptor, signaling mainly through cyclic AMP. The mechanisms are complementary on paper, but no published human randomized trial has tested the combination.
Ipamorelin peptide research rests on one genuinely important finding — a secretagogue that, in animal models, separated GH release from the cortisol and prolactin noise of its predecessors — and a much thinner human record than its online reputation suggests: one small pharmacokinetic study and one larger Phase 2 trial that missed its endpoint. Keep those two halves separate. Judged accurately, ipamorelin remains a valuable laboratory tool for studying selective GHS-R1a signaling and pulsatile GH release, which is exactly the purpose it is supplied for.
All Apex Bio Industries compounds are supplied strictly for laboratory research use only. This article is educational content about published research and regulatory status and does not constitute medical, safety, or usage advice. Research peptides are not for human or veterinary use, and nothing on this site should be interpreted as instructions for administration, dosing, or personal use.
Researchers comparing GH-axis tools can browse the full research peptides collection for related compounds. Combination formats are also available in the peptide blends collection.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
